Patents Examined by Julie Reeves
  • Patent number: 6306575
    Abstract: The present invention relates to an antibody composition which contains antibodies specific for glycophorin A, CD3, CD24, CD16, CD14, and optionally CD45RA, CD38, CD36, CD38, CD56, CD2, CD19, CD66e, CD66b, and/or antibodies specific for antigens expressed on non-hematopoietic tumor cells. A process is also provided for enriching and recovering human hematopoietic progenitor cells and stem cells in a sample containing human hematopoietic differentiated, progenitor, and stem cells, and optionally tumor cells.
    Type: Grant
    Filed: December 1, 1995
    Date of Patent: October 23, 2001
    Assignee: StemCell Technologies, Inc.
    Inventors: Terry Thomas, Peter Lansdorp
  • Patent number: 6218149
    Abstract: This invention provides a method of altering the affinity of an antibody for the antigen to which it is directed which comprises introducing into the variable region of the antibody a carbohydrate recognition site under conditions such that a carbohydrate binds to the site and thus attaches to the antibody. This invention also provides a method of modifying the carbohydrate content of an antibody which comprises deleting from a constant region of the antibody a carbohydrate recognition site which naturally occurs in such constant region of such antibody. Antibodies, e.g., monoclonal antibodies and human monoclonal antibodies, diagnostic test kits, DNA encoding antibodies, therapeutic agents, and methods for detecting the presence of a substance in a sample, and for recovering and purifying a substance from a sample are also provided.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: April 17, 2001
    Assignee: The Trustees of Columbus University in the City of New York
    Inventors: Sherie L. Morrison, Vernon T. Oi, Paul R. Hinton
  • Patent number: 6096871
    Abstract: Polypeptides that are cleared from the kidney and do not contain in their original form a Fc region of an IgG are altered so as to comprise a salvage receptor binding epitope of an Fc region of an IgG and thereby have increased circulatory half-life.
    Type: Grant
    Filed: April 14, 1995
    Date of Patent: August 1, 2000
    Assignee: Genentech, Inc.
    Inventors: Leonard G. Presta, Bradley R. Snedecor
  • Patent number: 6087174
    Abstract: The present invention provides a method of treating cancer comprising (a) obtaining a tumor cell line, (b) modifying the tumor cell line to render it capable of producing an increased level of a cytokine relative to the unmodified tumor cell line, and (c) administering the tumor cell line to a mammalian host having at least one tumor that is the same type of tumor as that from which the tumor cell line was obtained, wherein the tumor cell line is allogeneic and is not MHC-matched to the host. The present invention also provides a pancreatic tumor cell line, a method and medium for obtaining such a tumor cell line, and a composition comprised of cells of a purified pancreatic tumor cell line.
    Type: Grant
    Filed: March 18, 1998
    Date of Patent: July 11, 2000
    Assignee: Johns Hopkins University, School of Medicine
    Inventors: Elizabeth M. Jaffee, Drew M. Pardoll, Hyam I. Levitsky
  • Patent number: 6072035
    Abstract: The invention relates to reshaped human monoclonal antibodies directed against isotypic determinants of immunoglobulin E (IgE), direct equivalents and derivatives of said antibodies. The molecules of the invention are useful for diagnostics, prophylaxis and treatment of allergy.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 6, 2000
    Assignees: Novartis Corporation, Tanox Biosystems, Inc.
    Inventors: Norman Hardman, Frank Kolbinger, Jose Saldanha
  • Patent number: 6066719
    Abstract: This invention describes the production of bivalent linear F(ab').sub.2 fragments comprising tandem repeats of a heavy chain fragment V.sub.H -C.sub.H 1-V.sub.H -C.sub.H 1 cosecreted with two light chains, so as to form two functional antigen binding sites, wherein both the C-terminus of the first C.sub.H 1 is directly joined by a peptide bond to the N-terminus of the second V.sub.H.
    Type: Grant
    Filed: March 6, 1997
    Date of Patent: May 23, 2000
    Assignee: Genetech, Inc.
    Inventor: Gerardo A. Zapata
  • Patent number: 6027905
    Abstract: The invention provides a wide range of methods and compositions for detecting and treating cervical cancer in an individual. Specifically, the invention provides target cervical cancer-associated proteins, which permit a rapid detection, preferably before metastases occur, of cervical cancer. The target cervical cancer-associated protein, may be detected, for example, by reacting the sample with a labeled binding moiety, for example, a labeled antibody capable of binding specifically to the protein. The invention also provides kits useful in the detection of cervical cancer in an individual. In addition, the invention provides methods utilizing the cervical cancer-associated proteins either as targets for treating cervical cancer or as indicators for monitoring of the efficacy of such a treatment.
    Type: Grant
    Filed: December 11, 1997
    Date of Patent: February 22, 2000
    Assignee: Matritech, Inc.
    Inventors: Susan K. Keesee, Robert Obar, Ying-Jye Wu
  • Patent number: 6020146
    Abstract: The present invention is directed to an in vitro method for detecting the presence of carcinogenic agents.
    Type: Grant
    Filed: September 17, 1997
    Date of Patent: February 1, 2000
    Assignee: The Research Foundation State University of New York
    Inventor: Bozidar Djordjevic
  • Patent number: 6015680
    Abstract: The monoclonal antibody produced by a hybridoma cell strain TRD-L1, -L2 or -L3 which is obtained by the fusion between mouse myeloma cells and spleen cells of a mouse immunized with a human lung adenocarcinoma cell secretion component reacts in a specific fashion with a glycoprotein antigen that has a molecular weight of 200 kD or more (SDS-PAGE) and is present in human lung adenocarcinoma cells. It can be used efficiently in cancer diagnosis.
    Type: Grant
    Filed: September 12, 1997
    Date of Patent: January 18, 2000
    Assignee: Terumo Kabushiki Kaisha
    Inventors: Kouichi Tsuji, Yoshihiro Yoshida, Takashi Uwano
  • Patent number: 6013765
    Abstract: A new family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as DAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as GAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigens, and their precursor molecules are described.
    Type: Grant
    Filed: April 9, 1997
    Date of Patent: January 11, 2000
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Pierre Coulie, Hideyuki Ikeda, Thierry Boon-Falleur
  • Patent number: 6011138
    Abstract: Anti-human CD23 monoclonal antibodies containing human gamma 1 constant domains and therapeutic uses are provided. These antibodies inhibit IL-4 induced IgE production by B-cells significantly greater than antibodies containing other constant domains.
    Type: Grant
    Filed: February 20, 1997
    Date of Patent: January 4, 2000
    Assignees: IDEC Pharmaceuticals Corporation, Seikagaku Corporation
    Inventors: Mitchell E. Reff, William S. Kloetzer, Takehiko Nakamura
  • Patent number: 6011139
    Abstract: Isolated polypeptides useful in ameliorating GAD-associated autoimmune disease as well as diagnostic and therapeutic methods of using the peptides are disclosed. Monoclonal antibodies specific for GAD peptides and hybridoma cells producing such are also disclosed.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 4, 2000
    Assignee: The Regents of the University of California
    Inventors: Allan J. Tobin, Mark G. Erlander, Daniel L. Kaufman
  • Patent number: 6008023
    Abstract: The invention relates to the cytoplasmic expression of antibodies, antibody fragments and antibody fragment fusion molecules in E. coli. In particular, antibody fragment fusion molecules having an antibody moiety which is directed against tumors and an enzyme moiety which cleaves a nontoxic prodrug to give the toxic drug can be advantageously prepared in this way while retaining their respective functional properties.
    Type: Grant
    Filed: April 10, 1996
    Date of Patent: December 28, 1999
    Assignee: Hoechst Marion Roussel Deutschland GmbH
    Inventors: Martin Opper, Klaus Bosslet, Joerg Czech
  • Patent number: 6004782
    Abstract: A method for overexpressing a bioelastic polypeptide in a host cell is provided. A nucleic acid encoding a bioelastic polypeptide having pentapeptide, tetrapeptide, hexapeptide or nonapeptide repeating units is introduced into a host cell. The host cell is grown under conditions that provide for expression of the polypeptide as at least 40% of the total cellular protein of the host cell.
    Type: Grant
    Filed: October 13, 1995
    Date of Patent: December 21, 1999
    Assignees: Bioelastics Research Ltd., The UAB Research Foundation
    Inventors: Henry Daniell, David T. McPherson, Dan W. Urry, Jie Xu
  • Patent number: 5998586
    Abstract: An effective anti-IL-5 recombinant antibody molecule comprising heavy and/or light chain antigen-binding residues from a donor antibody.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 7, 1999
    Assignee: Celltech Therapeutics, Limited
    Inventors: Mark William Bodmer, Diljeet Singh Athwal, John Spencer Emtage
  • Patent number: 5986064
    Abstract: The present invention provides a human tumor-associated Kazal inhibitor (HuKI) and polynucleotides which identify and encode HuKI. The invention also provides expression vectors, host cells, antibodies and antagonists. The invention also provides methods for the prevention and treatment of diseases associated with expression of HuKI, as well as diagnostic assays.
    Type: Grant
    Filed: December 3, 1998
    Date of Patent: November 16, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Karl J. Guegler, Purvi Shah
  • Patent number: 5977323
    Abstract: Two novel cytokines which are involved in an inflammatory response (inflammatory cytokines) are disclosed. The inflammatory cytokines have been isolated from activated peripheral blood, preferably monocytes adhered to plastic; or peripheral blood leukocytes induced with calcium ionophore and mezerin. The two cytokines are Gro .beta. and .gamma., and their cDNA and amino acid sequences are disclosed. The expression of the genes in various cells is presented. Assay and diagnostic utilities using the cytokines; recombinant materials and procedures; purification procedures; and monoclonal antibodies to the cytokines are also shown.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 2, 1999
    Assignees: Chiron Corporation, University of North Carolina at Chapel Hill
    Inventors: John Stephen Haskill, Peter Ralph, Danute E. Nitecki, George Martin
  • Patent number: 5977315
    Abstract: The present invention provides a monoclonal anti-idiotype antibody 3H1 that escapes immune tolerance and elicits a specific immune response to CEA in mice, rabbits, monkeys, and patients with advanced CEA-associated disease. This invention also provides compositions which can be used in the detection or treatment of CEA-associated tumors mimics a specific epitope on carcinoembryonic antigen and a hybridoma that produces 3H1.
    Type: Grant
    Filed: December 28, 1995
    Date of Patent: November 2, 1999
    Assignee: The Board of Trustees of the University of Kentucky
    Inventors: Malaya Chatterjee, Heinz Kohler, Sunil K. Chatterjee, Kenneth A. Foon
  • Patent number: 5972703
    Abstract: Disclosed are methods, compositions and uses of bone precursor cells. Bone precursor cells are cells which are not hematopietic and which can differentiate into osteoblasts upon exposure to a bone growth factor and deposit calcium into the extracellular matrix. In addition, methods of differentiating bone precursor cells into osteoblasts are disclosed. Bone precursor cells are useful in the treatment of certain bone related disorders and diseases such as, promoting fracture repair.
    Type: Grant
    Filed: August 12, 1994
    Date of Patent: October 26, 1999
    Assignee: The Regents of the University of Michigan
    Inventors: Michael W. Long, Kenneth G. Mann
  • Patent number: 5965405
    Abstract: Methods for preparing Fv fragments which lack linking polypeptides in eukaryotic cells are provided.
    Type: Grant
    Filed: December 13, 1993
    Date of Patent: October 12, 1999
    Assignee: Celltech Limited
    Inventors: Gregory Paul Winter, Lutz Riechmann, Geoffrey Thomas Yarranton, Mark William Bodmer, Raymond John Owens